Skip to main content


Page 1 of 4

  1. Carcinoid syndrome (CS) is a unique constellation of symptoms caused by release of vasoactive substances from neuroendocrine tumors (Pandit et al., StatPearls, 2022). Neuroendocrine tumors are rare with an ann...

    Authors: Aditi Sharma, Maria E. Fierro, Stella Pak, Keerthi Thallapureddy, Moyosore Awobajo, Dawn Hui and Prince Otchere
    Citation: Cardio-Oncology 2023 9:28
  2. 25% of all breast cancer patients have HER-2 overexpression. Breast Cancer patients with HER-2 overexpression are typically treated with HER-2 inhibitors such as Trastuzumab. Trastuzumab is known to cause a de...

    Authors: Prince Otchere, Olusola Adekoya, Samuel B. Governor, Naveen Vuppuluri, Akruti Prabhakar, Stella Pak, Oduro Oppong-Nkrumah, Francis Cook, Rudy Bohinc and Gregory Aune
    Citation: Cardio-Oncology 2023 9:26
  3. Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction.

    Authors: Matthew Dean, Min Jung Kim, Sharon Dimauro, Susan Tannenbaum, Garth Graham, Bruce T. Liang and Agnes S. Kim
    Citation: Cardio-Oncology 2023 9:23
  4. Many ca. survivors exhibit signs of IR, an important risk factor for the development of CAD. CAC scans offer a risk assessment of CV disease before cardiac damage has occurred. We investigated how IR affects C...

    Authors: N. Jacobi, S. Ortman, L. Buda and Daniel Duprez
    Citation: Cardio-Oncology 2023 9:21
  5. Despite the cardiotoxic effect of anthracycline on the left ventricle (LV) was totally identified. The assessment of the anthracycline effect on the right ventricle(RV) by conventional echocardiography was a c...

    Authors: Wafaa S. El-Sherbeny, Nesreen M. Sabry, Shaimaa B. El-Saied and Basma Elnagar
    Citation: Cardio-Oncology 2023 9:20
  6. Though the incidence of atrial fibrillation (AF) is increased in patients with cancer, the effectiveness of catheter ablation (CA) for AF in patients with cancer is not well studied.

    Authors: Sarju Ganatra, Sonu Abraham, Ashish Kumar, Rohan Parikh, Rushin Patel, Sumanth Khadke, Amudha Kumar, Victor Liu, Andrea Nathalie Rosas Diaz, Tomas G. Neilan, David Martin, Bruce Hook, Sourbha S. Dani, Aarti Asnani and Anju Nohria
    Citation: Cardio-Oncology 2023 9:19
  7. Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute co...

    Authors: Dae Hyun Lee, Sanjay Chandrasekhar, Michael D. Jain, Rahul Mhaskar, Kayla Reid, Sae Bom Lee, Salvatore Corallo, Melanie J. Hidalgo-Vargas, Abhishek Kumar, Julio Chavez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Rawan Faramand…
    Citation: Cardio-Oncology 2023 9:18
  8. Despite advances in chemotherapy, the drugs used in cancer treatment remain rather harmful to the cardiovascular system, causing structural and functional cardiotoxic changes. Positron-emission tomography asso...

    Authors: Mônica M. C. Becker, Gustavo F. A. Arruda, Diego R. F. Berenguer, Roberto O. Buril, Daniela Cardinale and Simone C. S. Brandão
    Citation: Cardio-Oncology 2023 9:17
  9. Immune checkpoint inhibitors (ICIs) are currently widely used for treatment of various types of cancers. ICI-induced myocarditis, though uncommon, accounts for high risk of major adverse cardiac events and mor...

    Authors: Khan O. Mohammad, Hanna Fanous, Sneha Vakamudi and Yan Liu
    Citation: Cardio-Oncology 2023 9:15
  10. Immune checkpoint inhibitor (ICI) myocarditis is associated with high morbidity and mortality. While endomyocardial biopsy (EMB) is considered a gold standard for diagnosis, the sensitivity of EMB is not well ...

    Authors: Jesus Jimenez, Nicolas Kostelecky, Joshua D. Mitchell, Kathleen W. Zhang, Chieh-Yu Lin, Daniel J. Lenihan and Kory J. Lavine
    Citation: Cardio-Oncology 2023 9:14
  11. Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor tre...

    Authors: Anthony F. Yu, Chau T. Dang, Justine Jorgensen, Chaya S. Moskowitz, Patricia DeFusco, Eric Oligino, Kevin C. Oeffinger, Jennifer E. Liu and Richard M. Steingart
    Citation: Cardio-Oncology 2023 9:13
  12. This study aimed to evaluate the association between preoperative hs-cTnI and long-term mortality and major adverse cardiovascular events (MACE) in colorectal cancer patients.

    Authors: Yitao Zhang, Zicheng Huang, Sutian Hu, Jinhong Si, Shiyao Cheng, Zhichong Chen, Jiaojie Xue, Xue Lou, Huajing Peng, Zequan Li, Mao Ouyang, Xiang Gao and Weijie Zeng
    Citation: Cardio-Oncology 2023 9:12
  13. Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role...

    Authors: Tomohiro Kaneko, Sakiko Miyazaki, Azusa Kurita, Ryoko Morimoto, Shun Tsuchiya, Naoki Watanabe, Tomoiku Takaku, Norio Komatsu and Tohru Minamino
    Citation: Cardio-Oncology 2023 9:11
  14. Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or ...

    Authors: Ali Mir, Yasra Badi, Seif Bugazia, Anas Zakarya Nourelden, Ahmed Hashem Fathallah, Khaled Mohamed Ragab, Mohammed Alsillak, Sarah Makram Elsayed, Abdulrahman Ibrahim Hagrass, Sawyer Bawek, Mohamad Kalot and Zachary L. Brumberger
    Citation: Cardio-Oncology 2023 9:10
  15. Prostate cancer has a very high prevalence among elder men, and this could potentially increase as longevity in many parts of the world is increasing. Early stages of prostate cancer can have surgical options,...

    Authors: Aswini Kumar, Aswanth Reddy and Arjun Sekar
    Citation: Cardio-Oncology 2023 9:9
  16. Several cohort studies aimed at demonstrating an increased risk of cancer incidence and mortality in patients with a pre-existing diagnosis of heart failure (HF); however, conflicting results have been reporte...

    Authors: Massimiliano Camilli, Juan Guido Chiabrando, Marco Lombardi, Marco Giuseppe Del Buono, Rocco Antonio Montone, Antonella Lombardo, Filippo Crea and Giorgio Minotti
    Citation: Cardio-Oncology 2023 9:8
  17. The many improvements in cancer therapies have led to an increased number of survivors, which comes with a greater risk of consequent/subsequent cardiovascular disease. Identifying effective management strateg...

    Authors: Sherry-Ann Brown, Brian Y. Chung, Krishna Doshi, Abdulaziz Hamid, Erin Pederson, Ragasnehith Maddula, Allen Hanna, Indrajit Choudhuri, Rodney Sparapani, Mehri Bagheri Mohamadi Pour, Jun Zhang, Anai N. Kothari, Patrick Collier, Pedro Caraballo, Peter Noseworthy and Adelaide Arruda-Olson
    Citation: Cardio-Oncology 2023 9:7
  18. Acute myocardial infarction (AMI) and cancer are diseases with high morbidity and mortality worldwide, bringing a serious economic burden, and they share some risk factors. The purpose of this study was to det...

    Authors: Jianfeng Ye, Luming Zhang, Jun Lyu, Yidan Wang, Shiqi Yuan, Zhifeng Qin, Yu Liu, Tao Huang, Jinwei Tian and Haiyan Yin
    Citation: Cardio-Oncology 2023 9:6
  19. Consensus guidelines recommend periodic screening for coronary artery disease (CAD) in Hodgkin lymphoma (HL) survivors treated with radiation therapy (RT) to the chest. However, the prognostic utility of scree...

    Authors: Sanjay Divakaran, Diana M. Lopez, Sean M. Parks, Jon Hainer, Andrea K. Ng, Ron Blankstein, Marcelo F. Di Carli and Anju Nohria
    Citation: Cardio-Oncology 2023 9:5
  20. Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML). While the HMA decitabine, in its ...

    Authors: Ankur Sheel, Junu Bae, Ashlee Asada, Gregory A. Otterson, Ragavendra R. Baliga and Kristin L. Koenig
    Citation: Cardio-Oncology 2023 9:4
  21. Cardiac hemangiomas are very rare benign cardiac tumors. They can present at any age and clinical presentation varies according to location and size. We encountered an 87-year-old woman with a left atrial hema...

    Authors: Leart Berdica, Erisa Kola, Daniela Nakuci, Edlira Horjeti and Mehdi Alimehmeti
    Citation: Cardio-Oncology 2023 9:3
  22. Cancer survivors with prior chest radiation therapy (CXRT) frequently present with atrial fibrillation, heart failure, and have higher overall long-term mortality. There are no data examining the utility of le...

    Authors: Meer R. Zafar, Ashutosh Sharma, Sunitha Shyam Sunder, Badri Karthikeyan, Makoto Nagahama, Andrew Atia, Ronak Bahuva, Saraswati Pokharel, Vijay Iyer, Sharma Kattel and Umesh C. Sharma
    Citation: Cardio-Oncology 2023 9:2
  23. There is limited data on the impact of cardiac disease on long term outcomes of allogeneic stem cell transplant (alloSCT). Our study aims to describe the incidence of late cardiac events after alloSCT, identif...

    Authors: Christine Auberle, Daniel Lenihan, Feng Gao and Amanda Cashen
    Citation: Cardio-Oncology 2023 9:1
  24. Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer ...

    Authors: Charlie Wang, Sophia Zoungas, Mabel Yan, Rory Wolfe, Andrew Haydon, Mark Shackleton, Mark Voskoboynik, Maggie Moore, Miles C. Andrews, Stephen J. Nicholls and Victoria Mar
    Citation: Cardio-Oncology 2022 8:23
  25. Paclitaxel-induced cardiac ischemia is a rare but life-threatening complication. Although it may be difficult to distinguish from hypersensitivity or infusion reactions, it should not be overlooked. We herein ...

    Authors: Shota Higami, Yusuke Tanaka, Tomomi Deguchi, Mariko Shiraishi and Yasuhiko Shiki
    Citation: Cardio-Oncology 2022 8:22
  26. The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to describe the spectrum of cardiovascular adverse events (cvAEs) by pres...

    Authors: Maria Sol Andres, Sivatharshini Ramalingam, Stuart D. Rosen, John Baksi, Rajdeep Khattar, Yulia Kirichenko, Kate Young, Nadia Yousaf, Alicia Okines, Robert Huddart, Kevin Harrington, Andrew J.S. Furness, Samra Turajlic, Lisa Pickering, Sanjay Popat, James Larkin…
    Citation: Cardio-Oncology 2022 8:21
  27. We report the case of a 59-year-old female patient with no previous cardiovascular disease treated for Breast cancer with Capecitabine. Shortly after starting treatment, she developed recurrent angina. An exer...

    Authors: George B. Strobel, Shiva P. Ponamgi, Attila Roka and Ahmed S. A. Aboeata
    Citation: Cardio-Oncology 2022 8:19
  28. Neo(adjuvant) systemic treatment regimens containing anthracyclines such as doxorubicin cause a significant risk of heart failure. These regimens are one of the corner stones of osteosarcoma treatment, and the...

    Authors: Julius C. Heemelaar, Jeroen Janson, Jerry Braun, Frank M. Speetjens, Michiel A. J. van de Sande, Juan D. V. Hugo, Daniela Q. C. M. Barge-Schaapveld, Saskia L. M. A. Beeres, Laurens F. Tops, Hans Gelderblom and M. Louisa Antoni
    Citation: Cardio-Oncology 2022 8:18
  29. Cancer chemotherapy using anthracyclines is associated with cardiotoxicity (CTX), and left ventricular ejection fraction (LVEF) analysis is not sensitive to early cardiotoxic changes. Left ventricular global l...

    Authors: Diogo Pereira Santos Sampaio, João Batista Masson Silva, Daniela do Carmo Rassi, Aguinaldo F. Freitas Jr and Salvador Rassi
    Citation: Cardio-Oncology 2022 8:17
  30. Breast cancer patients are at a particularly high risk of cardiotoxicity from chemotherapy having a detrimental effect on quality-of-life parameters and increasing the risk of mortality. Prognostic biomarkers ...

    Authors: Cameron Brown, Michael Mantzaris, Elpiniki Nicolaou, Georgia Karanasiou, Elisavet Papageorgiou, Giuseppe Curigliano, Daniela Cardinale, Gerasimos Filippatos, Nikolaos Memos, Katerina K. Naka, Andri Papakostantinou, Paris Vogazianos, Erietta Ioulianou, Christos Shammas, Anastasia Constantinidou, Federica Tozzi…
    Citation: Cardio-Oncology 2022 8:16
  31. Dedicated cardio-oncology services are emerging rapidly around the world in order to provide cardiovascular care (CV) for cancer patients. The perspectives of patients regarding their experience of cardiac sur...

    Authors: Jennifer White, Julie Byles, Trent Williams, Rossana Untaru, Doan T. M. Ngo and Aaron L. Sverdlov
    Citation: Cardio-Oncology 2022 8:14
  32. Reports of cardiac adverse events from oncology clinical trials often are at variance with reports derived from clinical observations or data-base reviews. These differences may lead to confusion, as different...

    Authors: Michael S. Ewer and Jay Herson
    Citation: Cardio-Oncology 2022 8:13
  33. Acute ischemic stroke (Stroke) and transient ischemic attacks (TIA) are known complications in cancer patients and those with atrial fibrillation (AF). The role AF plays in Stroke/TIA in the setting of cancer ...

    Authors: Alia Khamis, Ala Emad Shaban, Tamer Salhab Altamimi, Zakaria Walid Shkoukani and Ismail Hamam
    Citation: Cardio-Oncology 2022 8:12
  34. Anthracycline chemotherapy and thoracic radiation therapy (RT) are known causes of cardiomyopathy among cancer survivors, however, management guidelines for this population are lacking. In this study we descri...

    Authors: Arash Delavar, Catherine Boutros, Dana Barnea, Wendy L. Schaffer and Emily S. Tonorezos
    Citation: Cardio-Oncology 2022 8:11

    The Correction to this article has been published in Cardio-Oncology 2022 8:15

  35. During cancer treatment, patients have a significantly higher risk of developing cardiovascular complications such as hypertension. In this study, we investigated the internal relationships between hypertensio...

    Authors: Yanan Jiang, Chunpeng Shi, Songyu Tian, Fengnan Zhi, Xiuyun Shen, Desi Shang and Jinwei Tian
    Citation: Cardio-Oncology 2022 8:10
  36. Acute pericarditis is caused by the inflammation of the pericardium which can result in an effusion around the heart. Proton beam therapy causing radiation-induced pericarditis is not a well-known cause of per...

    Authors: Rahul Gupta, Muling Lin, Gary M. Freedman, Deborah W. Sundlof and Cheri Silverstein Fadlon
    Citation: Cardio-Oncology 2022 8:9
  37. Breast cancer survivors have reduced peak aerobic capacity (VO2peak) which may be related to latent or lingering chemotherapy induced cardiac damage. Nine, older (67 ± 3 years), long-term survivors (9.8 years) of...

    Authors: Rhys I. Beaudry, Mark J. Haykowsky, James P. MacNamara, Wesley J. Tucker, Roshni Rao, Barbara Haley and Satyam Sarma
    Citation: Cardio-Oncology 2022 8:8
  38. Anticancer therapy has the potential to cause unwanted cardiovascular side effects. Utilization of radiation therapy to treat tumors near the heart can result in radiation-induced valvular heart disease among ...

    Authors: Shivaraj Patil, Srinath-Reddi Pingle, Khalid Shalaby and Agnes S. Kim
    Citation: Cardio-Oncology 2022 8:7
  39. Chimeric antigen receptor T-cell (CART) therapy is a form of cellular immunotherapy used to treat hematologic malignancies. Major adverse cardiovascular events have been seen in CART patients who have high gra...

    Authors: Ashish Patel, Joshua Levenson, Ziyu Huang, Mounzer Agha and Kathleen Dorritie
    Citation: Cardio-Oncology 2022 8:6
  40. Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are major classes of immune checkpoint inhibitors that are increasingly used for ...

    Authors: Jiandong Zhou, Sharen Lee, Ishan Lakhani, Lei Yang, Tong Liu, Yuhui Zhang, Yunlong Xia, Wing Tak Wong, Kelvin King Hei Bao, Ian Chi Kei Wong, Gary Tse and Qingpeng Zhang
    Citation: Cardio-Oncology 2022 8:5
  41. Androgen deprivation therapy (ADT) and radiotherapy (RT) are the mainstay treatment for localized prostate cancer and recurrence after surgery. Cardiovascular (CV) toxicity of ADT is increasingly recognized, a...

    Authors: Youquan Li, Whee Sze Ong, Ma Than Than Shwe, Nelson Ling Fung Yit, Sheriff Zhan Hong Quek, Eric Pei Ping Pang, Wen Shen Looi, Wen Long Nei, Michael Lian Chek Wang, Melvin Lee Kiang Chua, Terence Wee Kiat Tan, Eu Tiong Chua, Choon Ta Ng and Jeffrey Kit Loong Tuan
    Citation: Cardio-Oncology 2022 8:4
  42. Checkpoint-inhibitor immunotherapies have had a profound effect in the treatment of cancer by inhibiting down-regulation of T-cell response to malignancy. The cardiotoxic potential of these agents was first de...

    Authors: Zachary L. Brumberger, Mary E. Branch, Max W Klein, Austin Seals, Michael D. Shapiro and Sujethra Vasu
    Citation: Cardio-Oncology 2022 8:3
  43. Cardiovascular diseases and cancer continue to be the two leading causes of death in the United States. While innovations in artificial intelligence, digital health, and telemedicine may revolutionize cardio-o...

    Authors: Sherry-Ann Brown, Craig Beavers, Hugo R. Martinez, Catherine H. Marshall, Iredia M. Olaye, Avirup Guha, David Cho, Alison Bailey, Carmen Bergom, Neha Bansal, Brenton Bauer and Richard K. Cheng
    Citation: Cardio-Oncology 2022 8:2

Annual Journal Metrics

  • Speed
    55 days to first decision for all manuscripts (Median)
    87 days to first decision for reviewed manuscripts only (Median)

    162,991 Downloads (2022)
    770 Altmetric mentions (2021)

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here